Northwire Canada EditionFriday, July 10, 2026
Northwire
ABX 51.91 −0.6% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.73 +9.3% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2% ABX 51.91 −0.6% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.73 +9.3% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2%
Other Routine +

Rocket Doctor AI Subsidiary Treatment.com Secures Year 2 NIH Funding to Advance AI-Powered Family Health History Tool

AI-driven telehealth platform scaling U.S. payer access while burning cash to fund growth and R&D.

Executive Summary
  • Rocket Doctor AI’s U.S. subsidiary, Treatment.com Inc., secured Year 2 funding from the NIH’s National Institute on Minority Health and Health Disparities.
  • The award provides over US $250,000 in additional capital, bringing cumulative program funding to over US $500,000.
  • The total award value is approximately US $2 million over the full project lifecycle, extending through May 31, 2027.
  • Funds will drive platform refinement, initiate multi-site U.S. pilot testing, enhance the Global Library of Medicine (GLM), and advance commercialization efforts focused on culturally responsive healthcare delivery.
  • This is a direct follow-up to the October 2025 announcement of the US $2 million NIH SBIR Phase 2 grant, confirming milestone execution rather than introducing new capital or strategic shifts.
Material Impact
  • Financial impact: The US $250,000 Year 2 tranche is immaterial to the company’s quarterly revenue of $737,103 and net loss of $4.64M. It serves as non-dilutive R&D funding that offsets a fraction of operating expenses.
  • Strategic impact: Validates the continued execution of the AI family health history tool roadmap and supports the GLM enhancement. However, it does not accelerate revenue recognition, alter the U.S. payer expansion timeline, or materially extend the cash runway.
  • Market pricing: The broader US $2M grant was announced in October 2025. The market has already priced in the grant award and its developmental milestones. This release confirms routine progress without introducing unexpected upside or downside.
AIDR · Price
Company Overview
  • Rocket Doctor AI operates an AI-powered digital health platform delivering physician-led virtual and hybrid care.
  • Core offerings include primary care, urgent care, chronic disease management, mental health services, and clinical decision support via the Global Library of Medicine (GLM).
  • The company has aggressively expanded its U.S. in-network payer reach to over 21 million insured members across California, New York, and Maryland.
  • Strategic initiatives include the acquisition of Alea Health (mental health AI), partnerships with academic institutions, municipal healthcare programs, and a national motorsports marketing campaign targeting underserved populations.
  • The business model relies on scaling payer contracts, leveraging AI to reduce administrative burden, and eventually monetizing B2B white-labeling and SaaS opportunities.
Read the original news release →

More from Rocket Doctor AI Inc.